Anti-CD73 Monoclonal Antibodies for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, particularly those involving solid tumors, face challenges due to the immunosuppressive effects of CD73, which promotes tumor progression and angiogenesis, leading to poor therapeutic responses and drug resistance.
Innovation Solution
Development of monoclonal antibodies (mAbs) that specifically bind to and inhibit human CD73, overcoming TGF-β-mediated inhibitory effects on immune cells and enhancing antitumor responses by mediating internalization of CD73 and inhibiting its enzymatic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are used, then treatment is administered, but therapeutic response is poor due to immunosuppression and drug resistance
Solution Approach 1:
The patent converts the harmful immunosuppressive effect of CD73 into a beneficial target for therapy. By developing monoclonal antibodies that specifically bind to and inhibit CD73, the treatment transforms the molecule's harmful role in promoting tumor progression into a therapeutic target, thereby improving therapeutic response while counteracting immunosuppression
Solution Approach 2:
The monoclonal antibodies serve as intermediary agents that mediate between the immune system and the tumor microenvironment. These antibodies bind to CD73 on tumor cells and immune suppressor cells, blocking the enzyme's activity and preventing it from mediating immunosuppression, thereby restoring antitumor immune responses
2Reliability
If CD73 activity is inhibited using mAbs or small molecular inhibitors, then antitumor effects are improved, but combination therapy complexity increases
Solution Approach 1:
The monoclonal antibodies are designed to perform multiple functions simultaneously: they bind to and inhibit CD73 enzymatic activity, block CD73-mediated immunosuppression, and can be combined with other therapies. This multi-functionality allows a single agent to address multiple aspects of tumor progression, reducing the need for complex combination regimens while maintaining enhanced antitumor effects
Data Source
AI summary
Provided herein are monoclonal antibodies (mAbs) that bind to human Cluster of Differentiation 73 (CD73). In particular, anti-CD73 mAbs are provided that bind to and inhibit the activity of human CD73.